15.47MMarket Cap-1.24P/E (TTM)
1.290High0.982Low478.85KVolume1.240Open1.180Pre Close514.93KTurnover4.45%Turnover RatioLossP/E (Static)15.58MShares3.62052wk High4.96P/B10.69MFloat Cap0.83152wk Low--Dividend TTM10.77MShs Float15.550Historical High--Div YieldTTM26.10%Amplitude0.831Historical Low1.075Avg Price1Lot Size
bioAffinity Technologies Stock Forum
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that CyPath® Lung, its noninvasive test to detect early-stage lung cancer, will be added to the U.S. Federal Supply Schedule, a procurement system that provides the...
bioAffinity Technologies, a leading player in the field of early cancer detection, recently reported an acceleration in sales growth of its revolutionary product, CyPath® Lung. This surge signifies a growing demand for innovative, non-invasive methods for early lung cancer detection and highlights the potential of CyPath® Lung to revolutionize the i...
No comment yet